to paclitaxel/carboplatin, prolongs survival in previously untreated patients with advanced non-small-cell lung cancer: preliminary results from the ECOG Lung Cancer: Secondary Analyses of the ECOG and PointBreak Trials. Eastern Cooperative Oncology Group (E) and PointBreak studies. ECOG demonstrated longer progression-free (PFS) and overall survival ( OS) with the addition of bevacizumab at a dose of 15 mg/m2.

Author: Bakree Zulumi
Country: Mauritania
Language: English (Spanish)
Genre: Business
Published (Last): 12 February 2007
Pages: 173
PDF File Size: 6.87 Mb
ePub File Size: 7.89 Mb
ISBN: 358-2-80544-148-9
Downloads: 40441
Price: Free* [*Free Regsitration Required]
Uploader: Mauzil

ECOG will continue to dominate current treatment recommendations and the only evidence-based regimen to which bevacizumab should reasonably be added as a standard remains carboplatin and paclitaxel.


Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Its precise contribution to increasing survival remains unclear. Paclitaxel—carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Analyzed separately, these trials support the administration of bevacizumab with carboplatin and paclitaxel, while its administration with gemcitabine underperforms for the survival end point and is not clinically relevant since gemcitabine is preferentially given to patients with squamous cell histology who are poor candidates for bevacizumab due to risk of pulmonary hemorrhage.

In that case, the doublet would likely be more tolerable and cost-effective. All the remaining authors have declared no conflicts of interest. Outcomes for elderly, advanced-stage non-small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: However, this was not a randomized comparison and therefore, is subject to bias.

Anti-angiogenic therapy continues to hold promise and clearly benefits some patients.

However, until data provide evidence to the contrary it can be hypothesized that a pemetrexed-based doublet would be equivalent to the carboplatin, paclitaxel, bevacizumab triplet [ 115 ].

It furthers the University’s objective of excellence in research, scholarship, and education by publishing worldwide. Recently, two additional randomized trials have provided us with new data on ecpg.


Nevertheless, it suggests that the addition of bevacizumab to paclitaxel-based doublet chemotherapy since its approval in the United States has not led to improved survival data in this Medicare population. The role of bevacizumab in the 499 setting remains unclear. Palliative chemotherapy improves the quality of life and prolongs survival in patients with metastatic non-small-cell lung cancer NSCLC.

Treating patients with EGFR sensitizing mutations: Chemotherapy was administered every 3 weeks for six cycles, and bevacizumab was administered every 3 weeks until disease progression was evident or toxic effects were intolerable.

Of interest, Zhu et al. One of these JO reached statistical significance in 45999 of the addition of bevacizumab 45599 the PFS end point [ 14 ]. A number of other anti-angiogenic agents have been investigated in exog stage NSCLC without success. Both bevacizumab and pemetrexed can be administered as maintenance and it will be crucial to determine if both the drugs together truly outperform the individual drugs in that setting. Molecular biomarkers in non-small-cell lung cancer: However, a search for reliable, predictive biomarkers allowing for patient selection continues [ 7 ].

Bevacizumab remains of interest in the adjuvant setting as currently investigated in ECOG Finally, predictive markers are needed.

Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer. The effect of bevacizumab on lower stage disease similarly remains unclear.

In luciferase-tagged breast cancer mouse models with metastases to lungs, metastasis formation was decreased with nab-paclitaxel and bevacizumab when compared with each drug alone [ 21 ]. Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma.

The primary end point was overall survival. Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer.


Maintenance chemotherapy for advanced non-small cell lung cancer: In mouse modeling of breast and lung cancers, a paclitaxel and bevacizumab combination is synergistic, potentially due to increased paclitaxel concentrations in the tumor secondary to the downregulation of vascular permeability [ 18 ].

There were 15 treatment-related deaths in the chemotherapy-plus-bevacizumab group, including 5 from pulmonary hemorrhage. In the phase III AVAiL trial, patients were treated with cisplatin and gemcitabine versus the triplet regimen with bevacizumab administered at either 7. A randomized phase III study of maintenance therapy with bevacizumab, pemetrexed, or a combination of bevacizumab and pemetrexed following carboplatin, paclitaxel and bevacizumab for advanced nonsquamous NSCLC: Erratum in N Engl J Med.

As discussed earlier, the paper is also diminished by the fact that individual patient data were not utilized and updates beyond those of the initial database were not carried out. Patients on both study arms continued with maintenance therapy either bevacizumab alone or bevacizumab and pemetrexed.

Sign In or Create an Account. This strategy has been only marginally successful.

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Of interest, only patients with non-squamous cell histology were eligible. Attempts to increase the activity of chemotherapy in a non-selective manner have included the addition of monoclonal antibodies, in particular, antibodies directed against the epidermal growth factor receptor EGFR or against the vascular endothelial growth factor VEGF.

Disclosure — in the Blink of an Eye. Clinical experience has generally been less favorable in gemcitabine-based trials [ 1920 ].